Multiple Sclerosis
Last updated: 01 November 2019
You can legally access new medicines, even if they are not approved in your country.
Learn more »Mavenclad (cladribine) has become the multiple sclerosis therapy of choice for 1 in 5 neurologists in Germany and the UK. Meanwhile, many European neurologists wait for Ocrevus (ocrelizumab).
Read more